Literature DB >> 6471116

Phenothiazines and breast cancer.

S Kanhouwa, J M Gowdy, J D Solomon.   

Abstract

This study, based in a psychiatric hospital, reviews the incidence of breast cancer in 93 patients who had received phenothiazines prior to developing breast cancer compared with a control group of 28 patients who did not receive phenothiazines. The results indicate no significant difference in the incidence of breast cancer between those patients receiving phenothiazines and those that did not. The retrospective study covered a period of 21 years. The overall incidence of breast cancer in 63,000 female patients was found to be 1.85/1,000 as compared with 2/1,000 in the general population.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6471116      PMCID: PMC2609832     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  3 in total

1.  Age and death in breast cancer.

Authors:  J M Gowdy; J D Solomon
Journal:  Br Med J       Date:  1979-07-21

2.  Inhibition of chemical carcinogenesis in the hamster cheek pouch by topical chlorpromazine.

Authors:  I S Levij; A Polliack
Journal:  Nature       Date:  1970-12-12       Impact factor: 49.962

3.  Neuroleptic-induced prolactin level elevation and breast cancer: an emerging clinical issue.

Authors:  P M Schyve; F Smithline; H Y Meltzer
Journal:  Arch Gen Psychiatry       Date:  1978-11
  3 in total
  6 in total

1.  The incidence of cancer in schizophrenic patients.

Authors:  P B Mortensen
Journal:  J Epidemiol Community Health       Date:  1989-03       Impact factor: 3.710

2.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

Review 3.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Cancer risk among users of neuroleptic medication: a population-based cohort study.

Authors:  S O Dalton; C Johansen; A H Poulsen; M Nørgaard; H T Sørensen; J K McLaughlin; P B Mortensen; S Friis
Journal:  Br J Cancer       Date:  2006-08-22       Impact factor: 7.640

Review 5.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

6.  Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.

Authors:  A N Johnston; W Bu; S Hein; S Garcia; L Camacho; L Xue; L Qin; C Nagi; S G Hilsenbeck; J Kapali; K Podsypanina; J Nangia; Y Li
Journal:  Breast Cancer Res       Date:  2018-05-19       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.